 | |
| Clinical data | |
|---|---|
| Other names | CX-546 |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C14H17NO3 |
| Molar mass | 247.294 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
CX-546 is anampakine drug developed byCortex Pharmaceuticals.
It has been proposed as a treatment forschizophrenia.[1] CX-546 was the second drug of note to come out of the Cortex research program, afterCX-516, but while it was an improvement over its predecessor in some respects, it still has problems with limited oralbioavailability.
However, CX-546 still represented a significant advance that led on to the development of newer compounds such asCX-614 andCX-717 with superior properties over the earlier drugs. CX-546 itself has been investigated for other applications, and most notably has been found to show significant efficacy in reversing therespiratory depression produced bysedative drugs such asopioids andbarbiturates.[2]
No effective respiratory stimulants are currently marketed for this application, with CX-546 being only the third drug discovered (afterBIMU-8 andBW373U86) that effectively relieves the respiratory depression induced byfentanyl without reducing the analgesic effects. CX-546 could be developed for this purpose, although it is more likely that Cortex will use newer and more potent analogues such asCX-1739 or CX-1763, which are likely to be more suitable for commercial development.[citation needed]
